Seres Therapeutics Inc

-0.09 (-1.42%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)571.43M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$7.32 Million
Adjusted EPS-$0.05
See more estimates
10-Day MA$6.30
50-Day MA$6.48
200-Day MA$16.49
See more pivots

Seres Therapeutics Inc Stock, NASDAQ:MCRB

200 Sidney Street, 4th floor, Cambridge, Massachusetts 02139
United States of America
Phone: +1.617.945.9626
Number of Employees: 155


Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.